Sonia Alejandra Romera

Sonia Alejandra Romera

Auto-generated profile, based on publicly available information

Sonia Alejandra Romera

Universidad del Salvador, Consejo Nacional de Investigaciones Cientificas y Tecnincas (CONICET), Argentina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2025 in Revista MVZ Córdoba
Verified
Journal Article
Open access
PDF file
SMSilvina Soledad Maidana
Silvina Soledad Maidana
CMClaudio Martinez
Claudio Martinez
FMFlorencia Celeste Mansilla
Florencia Celeste Mansilla
ADAntonella Donato
Antonella Donato
LWLeandro Wegrzyn
Leandro Wegrzyn
SRSonia Alejandra Romera
Sonia Alejandra Romera
Objetive. Conventional control measures for rhinotracheitis caused by bovine alphaherpesvirus 1 (BoAHV-1, IBR) include vaccination and hygienic measures for herd cattle. In this study, an antiparasitic (Ivermectin) drug was evaluated for the potential treatment of BoAHV-1 in bovines. Materials and Methods. Fifteen bovines were randomly assigned to three groups (n=5 per group). Group 1 received no treatment. Group 2 was subcutaneously vaccinated with 3 mL of a commercial inactivated BoAHV-1 vaccine (Biopoligen Air) 30 and 9 days prior to viral challenge. Group 3 was treated with ivermectin (IVOMEC 1%, 0.2 mg/kg) at 0 and 5 days post-challenge. All animals were challenged intranasal with 3 mL of virulent BoAHV-1 (107.5 TCID₅₀/mL). Clinical signs were scored daily for 22 days post-challenge (dpc), and nasal secretions were collected for 14 dpc to assess viral shedding. Results. The efficacy of Ivermectin in inhibiting BoAHV-1 replication during peak infection days was notable, demonstrating a reduction of 1.5-2.25 logs compared to the infection control group. This inhibition was significant on day 6, coinciding with the peak excretion observed in the infection control group. Although replication was significantly reduced in animals challenged and treated with IVM, a question that was not answered is whether this replication was sufficient to establish latency. Therefore, it remains pending for future investigations to immunosuppress and evaluate the reactivation of latency. Conclusions. The findings of this study demonstrate that Ivermectin administered at the beginning of the infection and with reinforcement at 5 days was effective in reducing clinical signs of disease and viral excretion following the BoAHV-1 challenge. These findings demonstrate the inhibitory effect of ivermectin on BoAHV-1 replication in vivo and offer an alternative complementary strategy for managing and controlling BoAHV-1 outbreaks.

2 January 2025 in Revista Veterinaria
Verified
Journal Article
Open access
PDF file
CFC. Ferreccio
C. Ferreccio
SMSilvina Soledad Maidana
Silvina Soledad Maidana
RTR. Tau
R. Tau
LCL. Di Ciaccio
L. Di Ciaccio
VSV. Spotorno
V. Spotorno
SRS. A. Romera
S. A. Romera
Caprine herpesvirus 1 (CpHV-1) is distributed worldwide, causing significant economic losses. The application of acyclovir interferes with viral replication to varying degrees of efficacy, but it does not prevent the establishment of latency. Due to the costs and side effects associated with synthetic drugs, the search for new chemotherapeutic agents is essential for the treatment and control of viral diseases. The objective of this study is to evaluate and compare the in vitro antiviral activity of three native plants from Argentina as a therapeutic antiviral treatment against CpHV-1. Larrea divaricata, Minthostachys verticillata and Parastrephia quadrangularis were used. Four parameters were analyzed: Cytotoxic Concentration 50 (CC50), Inhibitory Concentration 50 (IC50), quantification by plaque assay and viral titration. The L. divaricata extract showed the lowest cytotoxicity (2.4 mg ml-1). The best selectivity index (SI) was obtained with the M. verticillata extract (10). L. divaricata and P. quadrangularis extracts demonstrated the greatest antiviral effects, with reductions of 90% and 75%, respectively, compared to untreated controls, where the greatest reduction in plaque size was observed. The highest inhibition of viral replication observed in the viral titration quantification occurred when monolayers were treated with L. divaricata, resulting in at least a 35% reduction. The combination of assay with L. divaricata and M. verticillata showed the greatest reduction in viral titers. The overall results provide evidence that L. divaricata and M. verticillata could serve as potential sources for new anti-CpHV-1 drugs.

3 September 2025 in Analecta Veterinaria
Verified
Journal Article
Open access
PDF file
SRSonia Alejandra Romera
Sonia Alejandra Romera
PSPatrick Stephan Sebastian
Patrick Stephan Sebastian
NMNicolás Morel
Nicolás Morel
SNSantiago Nava
Santiago Nava
SMSilvina Soledad Maidana
Silvina Soledad Maidana
This work documents the presence of bovine alphaherpesvirus type 1 subtype 1(BoAHV-1.1) viral genome in Rhipicephalus microplus (R. microplus) ticks collected from cattle in Quimili, Santiago del Estero Province, in December 2019 and April 2021. PCR detection determined five (5/57) BoAHV positive ticks. These PCR products were sequenced and compared with the GenBank database. A 100% nucleotide identity of the fragments with the Argentinean isolates (BoAHV-1.1 strain 40841, 41184, FR and p898) was observed and viral species and subtype was confirmed by phylogenetic analysis. There is no information on tick-borne transmission of alphaherpesviruses from ruminants, so a first approach is a molecular detection of the viruses in ticks. This work describes the first evidence of molecular detection of ruminant alphaherpesvirus in R. microplus of Argentina. However, this finding does not imply that R. microplus is a biological vector of this virus. Instead, it demonstrates the presence of the viral genome in ticks from BoAHV-1 circulating cattle herds. To determine if R. microplus can be a vector of this virus, specific studies on vector competence and capacity need to be conducted.

13 August 2025 in Viruses
Verified
Journal Article
Open access
PDF file
RTRocío Lucía Tau
Rocío Lucía Tau
AMAna Marandino
Ana Marandino
FTFátima Torales
Fátima Torales
Fabrício S. CamposFabrício S. Campos
Fabrício S. Campos
RRRoehe MICHEL ROEHE
Roehe MICHEL ROEHE
SMSilvina Soledad Maidana
Silvina Soledad Maidana
Bubaline alphaherpesvirus 1 (BuHV-1) is a virus that belongs to the Varicellovirus genus within the Alphaherpesvirinae subfamily. While BuHV-1 infections in water buffaloes (Bubalus bubalis) are often subclinical, clinical manifestations have been reported. This study provides complete genome sequences of five BuHV-1 strains isolated in Argentina, marking the first genomic characterization of BuHV-1 from the Americas. Phylogenetic reconstructions based on whole-genome and coding sequences, along with analyses of glycoproteins C, D, and E, identified a distinct clade and divergent strains. Comparative genomic analyses with publicly available BuHV-1 and Bovine alphaherpesvirus 5 (BoHV-5) sequences showed nucleotide divergence of up to 1.3% among BuHV-1 strains, indicating significant intraspecific genetic diversity. Cross-neutralization assays revealed variable relationships between BuHV-1 and BoHV-5 strains. Some Argentinian BuHV-1 strains exhibited significant antigenic subtype differences compared to Bovine alphaherpesvirus 1 (BoHV-1). Recombination analyses uncovered events between BuHV-1 and bovine herpesviruses, suggesting a complex evolutionary history within mixed farming systems. The findings indicate that the monophyletic BuHV-1 clade, including the reference BuHV-1 isolate, is representative of the BuHV-1 species. The remaining strains, provisionally classified as BuHV-1 indeterminate (BuHV-1i), can be categorized based on specific clinical and antigenic properties. The identified heterogeneity has significant implications for diagnostic accuracy, vaccine development, and disease management strategies in buffalo populations worldwide.

20 October 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
SMSilvina Soledad Maidana
Silvina Soledad Maidana
CFCarola Ferreccio
Carola Ferreccio
AMAna Marandino
Ana Marandino
YPYanina Panzera
Yanina Panzera
RPRuben Pérez
Ruben Pérez
SRSonia Alejandra Romera
Sonia Alejandra Romera
Bovine alphaherpesvirus 1 (BoAHV-1) is a major cattle pathogen, and glycoprotein E (gE)-negative marker vaccines are widely used for disease control and to differentiate infected from vaccinated animals. The genomic architecture of this previously developed recombinant strain beyond the intended gE/lacZ locus had not been characterized at the genome-wide level. Here, we performed whole-genome sequencing of the parental Los Angeles (LA) strain and two passages of the recombinant BoAHV-1ΔgEβgal strain. In addition, plaque area was descriptively assessed in primary fetal bovine kidney cells using measurements from a single experimental run. In addition to the expected replacement of the US8/gE locus with a β-galactosidase cassette, we identified a previously undescribed 3704 nt deletion in the US region. This deletion removed the complete US1.67, US2, and US3 coding sequences, as well as the 5′ portion of US4/gG. PCR assays and Sanger sequencing of the amplicon spanning the breakpoint precisely mapped the junction. Comparative annotation showed that the parental genome contained 74 viral CDSs, whereas both vaccine passage genomes contained 69. In the plaque assay, the mean plaque area of p11 was 68.8% lower than that of the parental LA strain. These findings document an unintended structural alteration in a previously evaluated recombinant vaccine strain and illustrate how genome-wide sequencing can complement targeted molecular characterization by identifying changes outside the intended engineered locus.

23 October 2025 in COVID
Verified
Journal Article
Open access
PDF file
SMSilvina Soledad Maidana
Silvina Soledad Maidana
SRSonia Alejandra Romera
Sonia Alejandra Romera
AMAna Marandino
Ana Marandino
RTRocío Lucia Tau
Rocío Lucia Tau
JSJuan Mauel Shammas
Juan Mauel Shammas
RPRuben Pérez
Ruben Pérez
SARS-CoV-2 persists worldwide, driving the demand for effective antivirals that inhibit replication and limit the emergence of resistant variants. Lycorine, a non-nucleoside inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase, exhibits antiviral activity without direct mutagenic effects. Here, we examine the occurrence of single-nucleotide variants (SNVs) and insertions/deletions (indels) in SARS-CoV-2 B.1.499 strain during serial passages in Vero cells, comparing lycorine-treated cultures (2.5 and 5 µg/mL) with untreated controls. Whole-genome sequencing was used to assess mutation patterns and frequencies. Lycorine-treated passages displayed greater variant diversity than controls, with fixed mutations mainly affecting non-structural proteins (Nsp3-F1375A, Nsp5-L50F, and Nsp14-G265D) and the envelope protein (E-S6L). A 15-nucleotide deletion in the spike gene (QTQTN motif) occurred in both groups but became fixed only in untreated passages, suggesting negative selection under lycorine pressure. Notably, the L50F mutation in Nsp5, previously linked to nirmatrelvir resistance, was found exclusively in lycorine-treated passages. Additionally, a 1-nucleotide deletion in the accessory gene ORF8, detected only under lycorine treatment, resulted in a frameshift mutation that added four amino acids, potentially altering the protein’s function. Overall, lycorine induces a distinct mutation profile, favoring replication-related variants while suppressing deleterious deletions. These findings suggest potential mechanisms of cross-resistance and highlight the importance of monitoring resistance during clinical use.